Skip to main content

A governing scenario · Reviewed September 22, 2026

Kyle Austin
Beyond 100 days.

Austin's pharmacy and small-business experience identifies possible friction points, but a federal program still needs defined reimbursement and budget rules. Removing middleman costs does not guarantee savings reach patients.

A hypothetical presidency, not a claim of candidacy or an election forecast. Policy effects below are analytical possibilities conditional on authority, financing and delivery.

Person-specific focus · source-linked analysis

From a position to a governing program

The selected themes below come from this person’s series coverage. A source passage is separated from our analysis of implementation. The proposed federal pathway is an analytical translation, not a newly discovered promise. Unselected issues remain outside this review.

01 · Mixed executive and legislative authorities

Drug prices and payment intermediaries

Series context · Series discussion

His most substantive area, and the one he has lived: a pharmacist and pharmacy owner (Pharm406, Billings) who “understands the healthcare issues and corruption related to the healthcare industry,” campaigns on “Healthcare 2.0,” and has fought the Montana Board of Pharmacy over regulatory overreach to defend small businesses and consumer access rights. He frames his Senate run as a chance to bring health-care reform to Washington with “fewer middlemen and more common sense.” No bill text is published — the…

Read the full context: Health Care

What can start before the program is complete

Use existing purchasing, competition and transparency tools while defining the products, intermediaries and patients affected.

What must change for the result to endure

Legislate payment or benefit changes where needed, with safeguards for supply and continuity of treatment.

Drill down: failure modes and the test of success

Where it can stall: A lower reported price is not a patient saving if rebates, eligibility or availability change in the opposite direction.

Evidence that would change the assessment: Net and out-of-pocket prices, access denials, shortages, pharmacy closures and payer spending. Compare outcomes with the pre-policy baseline and affected groups that did not receive the intervention; distinguish outside shocks from the policy’s contribution.

Before assigning a net winner: obtain the actual proposal, funding source, affected population, transition plan and independent cost estimate. An announcement, sponsorship or appropriation alone does not establish the final effect.

02 · Legislation central

Spending restraint and program design

Series context · Series discussion

His top priority: small government. “Our government has gotten so big and it has gotten so costly to the Montana families... our taxes are out of control. Our cost of living is out of control... we need to DOGE the government on a federal level and even on the state level; to cut government spending so we can lower taxes.” He ties the size of government directly to cost-of-living pressure on families.

Read the full context: Fiscal Policy and Government Size

What can start before the program is complete

Audit costs and performance, naming the functions affected before assuming a saving is achievable.

What must change for the result to endure

Change appropriations or statutes where required and finance an orderly transition for continuing obligations.

Drill down: failure modes and the test of success

Where it can stall: Across-the-board reductions can cut productive capacity along with waste, and executive control over appropriations is limited.

Evidence that would change the assessment: Net savings after transition costs, service outcomes, maintenance backlogs, displaced obligations and independent audit results. Compare outcomes with the pre-policy baseline and affected groups that did not receive the intervention; distinguish outside shocks from the policy’s contribution.

Before assigning a net winner: obtain the actual proposal, funding source, affected population, transition plan and independent cost estimate. An announcement, sponsorship or appropriation alone does not establish the final effect.

03 · Mixed executive and legislative authorities

Permitting and regulatory delivery

Series context · Series discussion

A small-business owner running against regulatory burden: the February 28, 2026 Board of Pharmacy appearance to “challenge regulatory overreach and defend small businesses and consumer access rights” is the documented action; “honest government” and anti-corruption framing run through his campaign materials.

Read the full context: Regulation and Small Business

What can start before the program is complete

Identify the exact approval steps, agency capacity and statutory authority before changing timelines or enforcement priorities.

What must change for the result to endure

Legislate changes where required and fund the review capacity needed to maintain predictable, defensible decisions.

Drill down: failure modes and the test of success

Where it can stall: Court reversals and understaffed review agencies can erase nominal gains in speed.

Evidence that would change the assessment: Approval-to-construction conversion, decision time, litigation reversals, compliance costs and adverse incidents. Compare outcomes with the pre-policy baseline and affected groups that did not receive the intervention; distinguish outside shocks from the policy’s contribution.

Before assigning a net winner: obtain the actual proposal, funding source, affected population, transition plan and independent cost estimate. An announcement, sponsorship or appropriation alone does not establish the final effect.

Beyond the opening hundred days

How Austin’s agenda could develop

Choose the governing conditions. These scenarios test mechanisms and tradeoffs; they do not assign election odds, assume passage, or predict a numerical economic result.

Assume the specific proposal wins the votes and funding it requires; party control alone is insufficient.

Years 1–2

Use the first two years to enact the specified law, finish required procedures and start delivery.

Years 3–4

By years 3–4, evaluate actual use, costs and unintended effects; amend or stop ineffective components.

Years 5–10

In years 5–10, assess whether later governments retain the law, financing and operating capacity. This horizon does not assume reelection.

Chart 4 · From agenda to durable governance
ThemeWhat this scenario requiresWhat can interrupt it
Drug prices and payment intermediariesLegislate payment or benefit changes where needed, with safeguards for supply and continuity of treatment.A lower reported price is not a patient saving if rebates, eligibility or availability change in the opposite direction.
Spending restraint and program designChange appropriations or statutes where required and finance an orderly transition for continuing obligations.Across-the-board reductions can cut productive capacity along with waste, and executive control over appropriations is limited.
Permitting and regulatory deliveryLegislate changes where required and fund the review capacity needed to maintain predictable, defensible decisions.Court reversals and understaffed review agencies can erase nominal gains in speed.

Conditional winners and losers

Who could gain—and who could bear costs

Chart 5 · Qualitative exposure map. These groups can overlap: the same person can gain as a worker and pay more as a consumer or taxpayer. No net ranking is possible without specified legislation, financing and independent estimates.

The channels below assume the relevant policy is enacted and delivered as designed. Benefits remain conditional on implementation.

Drug prices and payment intermediaries

Potential beneficiaries

Patients and payers could gain if negotiated savings reach the pharmacy counter and preserve access.

Potential costs and risks

Manufacturers, intermediaries and some providers may lose revenue; supply and investment effects depend on the payment design.

Check the result: Net and out-of-pocket prices, access denials, shortages, pharmacy closures and payer spending.

Spending restraint and program design

Potential beneficiaries

Taxpayers or competing priorities could benefit if ineffective spending is actually removed.

Potential costs and risks

Service recipients, employees and contractors can lose income or access; deferred maintenance can raise later costs.

Check the result: Net savings after transition costs, service outcomes, maintenance backlogs, displaced obligations and independent audit results.

Permitting and regulatory delivery

Potential beneficiaries

Projects delayed by avoidable administrative friction and the workers or users they serve could benefit.

Potential costs and risks

Communities, workers or ecosystems can bear external costs if substantive safeguards are weakened rather than duplicated steps removed.

Check the result: Approval-to-construction conversion, decision time, litigation reversals, compliance costs and adverse incidents.

Keep the source trail intact

Original articles and citations

The original reporting and analysis remain unchanged. Citations below are retained from those articles and are not all independently revalidated in this extension. Consult the linked passage, date and underlying document before treating a proposal or officeholding assertion as established fact.

All 1 series article

View 10 preserved external citations
  1. Kyle Austin for U.S. Senate — campaign site: platform, press releases, debate challenge (kyleaustinmt.com) (article context)
  2. Montana Free Press — 2026 Montana Election Guide: Kyle Austin, U.S. Senate (primary results) (article context)
  3. Libertarian Party — Kyle Austin, candidate for U.S. Senate, Montana (candidate bio) (article context)
  4. Montana Public Radio — Q&A: Kyle Austin, Libertarian U.S. Senate candidate (Austin Amestoy, May 6, 2026) (article context)
  5. NBC Montana — Kyle Austin hopes to improve health care with U.S. Senate run (Beyond the Podium) (article context)
  6. KTVH Helena — Libertarian U.S. Senate candidate Austin on the road campaigning (article context)
  7. The Midterm Project — Kyle Austin, U.S. Senate candidate (Libertarian, Montana): FEC filings and race rating (article context)
  8. Federal Election Commission — AUSTIN, KYLE, candidate overview (Montana U.S. Senate, 2026) (article context)
  9. KTVH Helena (YouTube) — Libertarian U.S. Senate candidate Austin on the road campaigning (article context)
  10. Hero photo — Montana State Capitol, Helena, David Wilson, via Wikimedia Commons (article context)

Framework for the new analysis

The framework sources explain institutions and constraints; they do not support a numerical forecast or endorse these scenarios. Read the full method ↗